If you’re considering buying P

If you’re considering buying ProKidney Corp. (ticker PROK) for the long term, one compelling reason is:

> Potential of its lead therapy to address a large unmet medical need.

ProKidney is developing a cell-therapy platform (namely REACT / “renal autologous cell therapy”) aimed at treating chronic kidney disease (CKD) in diabetic patients, a market with few disease-modifying options.

Because CKD affects many people and presents serious complications (e.g., kidney failure, dialysis), if REACT succeeds in later-stage trials and gets regulatory approval, the company could have a strong growth opportunity.

Cautious:

The company is still in clinical stage (no commercial product yet), so there is significant risk of trial failure or regulatory setbacks.

Analysts are mixed: some bullish (high upside if things go well), others cautious.

For long-term holding, you must be comfortable with biotech risk (protocols, timelines, cash burn, competition, etc).

Sorry, this post has been deleted

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

CyrilDavy
10-30
CyrilDavy
Interesting potential

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":494531441910040,"tweetId":"494531441910040","gmtCreate":1761745171208,"gmtModify":1761791568183,"author":{"id":3575196385895354,"idStr":"3575196385895354","authorId":3575196385895354,"authorIdStr":"3575196385895354","name":"Cedric77","avatar":"https://static.tigerbbs.com/e5ee082b05004f20d3486afedee30814","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.15","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":220,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body>If you’re considering buying ProKidney Corp. (ticker PROK) for the long term, one compelling reason is:\n&gt; Potential of its lead therapy to address a large unmet medical need.\nProKidney is developing a cell-therapy platform (namely REACT / “renal autologous cell therapy”) aimed at treating chronic kidney disease (CKD) in diabetic patients, a market with few disease-modifying options.\nBecause CKD affects many people and presents serious complications (e.g., kidney failure, dialysis), if REACT succeeds in later-stage trials and gets regulatory approval, the company could have a strong growth opportunity.\nCautious:\nThe company is still in clinical stage (no commercial product yet), so there is significant risk of trial failure or regulatory setbacks.\nAnalysts are mixed: some bullish (high upside if things go well), others cautious.\nFor long-term holding, you must be comfortable with biotech risk (protocols, timelines, cash burn, competition, etc).</body></html>","htmlText":"<html><head></head><body>If you’re considering buying ProKidney Corp. (ticker PROK) for the long term, one compelling reason is:\n&gt; Potential of its lead therapy to address a large unmet medical need.\nProKidney is developing a cell-therapy platform (namely REACT / “renal autologous cell therapy”) aimed at treating chronic kidney disease (CKD) in diabetic patients, a market with few disease-modifying options.\nBecause CKD affects many people and presents serious complications (e.g., kidney failure, dialysis), if REACT succeeds in later-stage trials and gets regulatory approval, the company could have a strong growth opportunity.\nCautious:\nThe company is still in clinical stage (no commercial product yet), so there is significant risk of trial failure or regulatory setbacks.\nAnalysts are mixed: some bullish (high upside if things go well), others cautious.\nFor long-term holding, you must be comfortable with biotech risk (protocols, timelines, cash burn, competition, etc).</body></html>","text":"If you’re considering buying ProKidney Corp. (ticker PROK) for the long term, one compelling reason is: > Potential of its lead therapy to address a large unmet medical need. ProKidney is developing a cell-therapy platform (namely REACT / “renal autologous cell therapy”) aimed at treating chronic kidney disease (CKD) in diabetic patients, a market with few disease-modifying options. Because CKD affects many people and presents serious complications (e.g., kidney failure, dialysis), if REACT succeeds in later-stage trials and gets regulatory approval, the company could have a strong growth opportunity. Cautious: The company is still in clinical stage (no commercial product yet), so there is significant risk of trial failure or regulatory setbacks. Analysts are mixed: some bullish (high upside if things go well), others cautious. For long-term holding, you must be comfortable with biotech risk (protocols, timelines, cash burn, competition, etc).","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/494531441910040","repostId":2576064399,"repostType":2,"isVote":1,"tweetType":1,"viewCount":596,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":true,"length":817,"optionInvolvedFlag":true,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":494723738030784,"commentId":"494723738030784","gmtCreate":1761792113589,"gmtModify":1761834456675,"authorId":9000000000000641,"author":{"id":9000000000000641,"idStr":"9000000000000641","authorId":9000000000000641,"name":"CyrilDavy","avatar":"https://static.tigerbbs.com/fd67ba4a6ca5ca66b27af6afcce989dc","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":494531441910040,"objectIdStr":"494531441910040","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Interesting potential","text":"Interesting potential","html":"Interesting potential","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/494531441910040"}